Breast Cancer Screening Market

Global Breast Cancer Screening Market Size (2023 to 2028)

The worldwide breast cancer screening market is estimated to be USD 2336 million by 2028 from USD 1811 million in 2023, growing at a CAGR of 5.22% from 2023 to 2028.

Breast cancer screening is done to detect cancer in its early stages and ensure that patients receive prompt treatment. Breast cancer is classified into several kinds based on the type of cancerous breast cell. Different breast regions, such as the ducts and lobes, might be affected by breast cancer. The most common cancer among women is breast cancer. As people live longer, adapt to Western habits, and become more urbanized, breast cancer is becoming more common in low-income countries. Due to a lack of suitable breast screening programs in these countries, more than half of all breast cancer cases are currently reported from low-and-middle-income countries (LMICs), resulting in late detection of cases. 

MARKET DRIVERS:

The rising awareness about early detection of breast cancer, the increasing incidence of breast cancer, and the expanding government initiatives and support contribute to the rise of the global breast cancer screening market.

Breast cancer is the most frequent type of cancer in women, affecting 2.1 million women each year and accounting for most cancer-related fatalities in women. Breast cancer can be detected early, leading to better results such as a higher survival rate, more treatment options, and a higher quality of life. The demand for breast cancer screening tests is increasing due to the growing necessity for these tests in both developing and developed countries, which is driving the expansion of this market. In addition, the rising prevalence of breast cancer will necessitate more diagnostic equipment, which will drive up demand for the breast cancer screening market. For instance, 685,000 people worldwide died in 2020 because of breast cancer, which affected 2.3 million women. The most common cancer globally as of the end of 2020 was breast cancer, which had been diagnosed in 7.8 million women in the previous five years, according to statistics from WHO. 

The testing adoption is projected to expand as reimbursement and insurance coverage increase. Government organizations have approved several tests for reimbursement worldwide. In the breast cancer diagnostics market, technological advancement is a significant trend. Several novel approaches have been developed that could be useful in detecting and treating breast cancer. For example, breast tomosynthesis, or 3D mammography, captures photos of the breast from various angles and converts them into a 3-D model. 

Furthermore, the growing technological advancements and involvement of key market players drive the market's growth. In addition, the new personalized approach toward treating cancer is augmenting the market's growth. 

MARKET RESTRAINTS:

The high expense of diagnosing breast cancer makes it a distant option, restricting the market growth for breast cancer screening. In addition, the breast cancer screening market challenges include fear, humiliation, perceptions of breast cancer and beliefs, lack of motivation, education, socioeconomic level, and poor experiences.

Impact of COVID-19 on the global breast cancer screening market:

With the World Health Organization (WHO) declaring the COVID-19 outbreak a pandemic, a host of established pharmaceutical and biopharmaceutical companies and small start-ups have rushed to develop treatments and vaccines to combat the infection caused by the novel coronavirus. The COVID-19 pandemic has had a substantial impact on hospital resources around the world. This has primarily been accomplished by drastically lowering inpatient and outpatient services for various diseases and instituting infection prevention and control methods. The number of cancer screening and diagnostic treatments has dropped dramatically, with the pandemic affecting countries worldwide.

The COVID-19 pandemic impacts mortality and morbidity, and disruptions are predicted to last for some time, making urgent cancer-related services challenging. Early detection and treatment of breast cancer are critical for increased survival and long-term quality of life. However, health services have been stressed in general, and efforts to discover and treat breast cancers early have been delayed or decreased in many settings with population breast mammography screening. International expert partnerships from the CCGMC Working Group 2 (Breast Cancer) will perform analysis and modeling studies to inform critical stakeholders' recovery efforts to limit the pandemic's impact on early breast cancer detection and treatment.

REPORT COVERAGE:

This research report on the global breast cancer screening market has been segmented and sub-segmented based on type, application, end-user, and region.

Breast Cancer Screening Market – By Type:

• Imaging
• Biopsy
• Genomic Tests
• Blood Tests
• Others

The global breast cancer screening market is expected to dominate the imaging tests segment during the forecast period. The imaging test is the most often used screening test for breast cancer, and these imaging tests are also the most trustworthy. Therefore, mammograms are the most often used screening diagnostics for breast cancer. Because mammography is the gold standard procedure for detecting breast cancer, governments and other healthcare organizations worldwide are working to make mammography screening available to women aged 50 to 75. This is driving up demand for mammography across the globe, while laboratory and blood testing and other imaging tests are becoming more popular.

Breast Cancer Screening Market – By Product:

• Platform-based Products
  • Next-generation Sequencing
  • Microarrays
  • PCR
  • Others
• Instrument-based Products
  • Imaging
  • Biopsy

During the forecast period, the instrument-based product segment will dominate the market for breast cancer screening. For widespread population-based screening of breast cancer patients, imaging is the first approach. People living with Breast cancer must have a biopsy to confirm their diagnosis. Many organizations, such as the National Breast Cancer Foundation, Inc., are working to raise awareness about breast cancer, the importance of early detection, and treatment choices.

However, the platform-based products segment is also expected to show significant growth due to the rise in market research and development activities. Processes like PCRs and Microarrays are now easier to perform due to readily available buffers and research tracking software, along with the availability of CROs for better research in drug development. 

Breast Cancer Screening Market – By Application:

• Screening
• Diagnostic and Predictive
• Prognostic
• Research

The diagnostics and predictive application segment dominated the global breast cancer screening market in 2022. The growing popularity of genetic testing may contribute to the segment's expansion. Furthermore, advancements in this discipline, such as the creation of biomarkers, may aid in developing the breast cancer screening market.

However, the research segment is also expected to augment growth in the market due to rising awareness of women's health and funding for research activities. For example, according to national cancer research, researchers supported by the NCI are advancing our knowledge of breast cancer prevention, detection, and treatment. Additionally, they are examining ways to reduce inequalities and raise the standard of living for disease survivors. One such research is the clinical trial for TAILORx, sponsored by NCI. A test that examines the expression of specific genes can identify which women can safely forgo chemotherapy, according to the study, which involved patients with ER-positive, lymph node-negative breast cancer.

Breast Cancer Screening Market – By End-user:

• Hospitals & Clinics
• Diagnostic Centers and Medical Laboratories
• Others

During the forecast period, the hospitals and clinics segment will dominate the market for breast cancer screening. Rising patient hospitalizations and disease burden likely fuel the segment's expansion. Patients undergo biopsies for confirmation testing in hospitals after the screening test. Furthermore, PET, CT, and MRI are utilized to monitor disease development and assess the efficacy of cancer treatments.

However, diagnostic centers and medical diagnostics segments are also expected to show significant growth in the market. The increasing emphasis on disease prevention and the benefits of early diagnosis are helping the segment's growth. The technological advancements in diagnostic procedures for breast cancer also support the market's growth. For example, the new Breast tomosynthesis, often known as 3-D mammography, is one technological advancement. This process creates a 3-D-looking image of the breast using photographs taken at various angles all around the breast.

Breast Cancer Screening Market – By Region:

• North America
• Asia Pacific
• Europe
• Latin America
• The Middle East and Africa

Geographically, the North American region held the majority of the global breast cancer screening test market share in 2022 and is anticipated to continue the same trend throughout the forecast period. The United States had the most significant share in the North American region in 2020. This is primarily due to rising breast cancer incidence rates and increased public awareness of the need for early cancer detection. In addition, the presence of well-developed healthcare infrastructure in the United States is projected to move the market forward.

Due to the rising incidence of breast cancer and the adoption of advanced diagnostic techniques, the market for breast cancer diagnostics in Asia is predicted to grow at the fastest rate over the forecast period. Furthermore, the market expansion will likely be aided by increasing reimbursement guidelines and expanding healthcare infrastructure. 

KEY MARKET PARTICIPANTS:

Companies playing a promising role in the global breast cancer screening market profiled in this report are Abbott Laboratories, Myriad Genetics Inc., Hologic Inc., Koninklijke Philips N.V., Fujifilm Holdings Corporation, GE Healthcare, Thermo Fischer Scientific Inc., Siemens AG, NanoString Technologies Inc., C. R. Bard Inc., Gamma Medica Inc., Aurora Imaging Technology Inc., Leica Biosystems Nussloch GmbH, bioTheranostics Inc., Bio-Rad Laboratories Inc., Illumina Inc., Biocept Inc., Epigenomics AG, AstraZeneca plc and Quest Diagnostics Incorporated.

RECENT MARKET DEVELOPMENTS:

• In November 2022, to enhance the detection of breast cancer and the evaluation of immediate personal cancer risk, Google Health and mammography artificial intelligence (AI) vendor iCAD, Inc. announced a strategic partnership to incorporate Google Health's AI technology into iCAD's portfolio of breast imaging AI solutions.
• In December 2022, At the 2022 San Antonio Breast Cancer Symposium (SABCS), held from December 6 to December 10, cancer screening and diagnostics company Exact Sciences presented clinical validation data for its breast cancer radiation signature, Profile for the Omission of Local Adjuvant Radiotherapy (POLAR).
• In December 2022, the molecular diagnostics business revealed that Exact Sciences has been presenting new findings from numerous trials supporting its cancer screening and diagnostic assays at the 2022 San Antonio Breast Cancer Symposium (SABCS) this month.
• In December 2022, The 108th Annual Radiological Society of North America (RSNA) meeting will take place from November 27–December 1, 2022, and ScreenPoint Medical will present Transpara, the top artificial intelligence (AI) breast care software in the world (South Hall #4141). This week at RSNA, research on the performance of Transpara is being presented. Two studies show that Transpara can safely reduce workload in the clinical workflow of a double-reading breast cancer screening program.
• Thermo Fisher Scientific, Inc. signed a deal with AstraZeneca and the University of Nebraska Medical Center in September 2020 to develop innovative clinical biomarkers.